Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitors

Patent metadata

Field	Value
Publication number	US-9340545-B2
Application number	US-201313865379-A
Country	US
Kind code	B2
Filing date	Apr 18, 2013
Priority date	Oct 18, 2010
Publication date	May 17, 2016
Grant date	May 17, 2016

Abstract

The present invention relates to the compound of formula (I)

and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.

First claim

The invention claimed is:

1. A compound of formula (I)

that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide in free base form.

2. A pharmaceutical composition comprising a compound according to claim 1 , in combination with one or more pharmaceutically acceptable diluents or carriers.

3. A pharmacutical composition comprising a compound of fomula (I)

that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-l-yl) methyl)-3-(2-chlorobenzyl) -4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide or a pharmaceutically acceptable salt thereof or a stereoisomer, tautomer or isotope thereof, in combination with lactose.

4. A pharmaceutical composition according to claim 3 , wherein the compound of formula (I) is in micronized form.

5. A dry powder pharmaceutical composition comprising a compound of formula (I)

that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin- 1 -yl) methyl)-3-(2 -chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide or a pharmaceutically acceptable salt thereof or a stereoisomer, tautomer or isotope thereof wherein the compound of formula (I) is in finely divided form.

6. A composition according to claim 3 wherein the compound of formula (I) has a mass median diameter (MMAD) of 1-10 μm.

7. A composition according to claim 3 , wherein the compound of formula (I) is micronized.

8. An intermediate of formula (II):

wherein LG 1 represents a leaving group;
or a protected derivate thereof.

Assignees

• Respivert Ltd
• Respivert Ltd

Inventors

• King-Underwood John
• Ito Kazuhiro
• Murray Peter John
• Hardy George
• Brookfield Frederick Arthur
• Brown Christopher John

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title